Drugs / Deoxyribonuclease
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT07095361 | Sep 2025 → Sep 2028 expected | empyema, pleural empyema, respiratory tract infectious disorder | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03468933 Comparator | Nov 2017 → Dec 2019 | empyema, pleuropneumonia | Tulane University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-03-13 | Xenetic Biosciences, Inc. | Results Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses xeneticbio.com ↗
Findings demonstrate that by degrading neutrophil extracellular traps (NETs), DNase I not only facilitates increased T cell infiltration but also restores T cell functionality, paving the way for more effective cancer treatment strategies |
| 2024-11-21 | Xenetic Biosciences, Inc. | Results Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis xeneticbio.com ↗ |
| 2013-06-20 | Protalix | Results Protalix BioTherapeutics Discloses Three New Compounds in Development protalix.com ↗
In preclinical trials, PRX-110 demonstrated improved enzyme kinetics, less sensitivity to inhibition by actin and improved ex-vivo efficacy when compared to Pulmozyme®, the only approved form of recombinant DNase 1 manufactured in Chinese hamster ovary (CHO) cells. |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Deoxyribonuclease | “instillation of intrapleural tissue Plasminogen Activator (TPA) and human recombinant Deoxyribonuclease (DNase) for the management of empyema or complicated parapneumonic...” NCT03468933 ↗2“Deoxyribonuclease (DNase) 5mg will be administered once a day as intrapleural enzyme therapy (IET) for 3 consecutive days.” NCT07095361 ↗ |
| Known as | DNase | “instillation of intrapleural tissue Plasminogen Activator (TPA) and human recombinant Deoxyribonuclease (DNase) for the management of empyema or complicated parapneumonic...” NCT03468933 ↗1“Deoxyribonuclease (DNase) 5mg will be administered once a day as intrapleural enzyme therapy (IET) for 3 consecutive days.” NCT07095361 ↗ |
| Modality | Protein / enzyme biologic | “human recombinant deoxyribonuclease” NCT03468933 ↗ |
| Route | Other | “receive intrapleural combination” NCT03468933 ↗ |